{"id":"NCT00680745","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","officialTitle":"A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-11","completion":"2010-05","firstPosted":"2008-05-20","resultsPosted":"2013-10-14","lastUpdate":"2013-10-14"},"enrollment":597,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes"],"interventions":[{"type":"DRUG","name":"dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Glimepiride","otherNames":["Amaryl"]},{"type":"DRUG","name":"metformin hydrochloride","otherNames":["Glucophage"]},{"type":"DRUG","name":"pioglitazone hydrochloride","otherNames":["Actos"]},{"type":"DRUG","name":"Rosiglitazone","otherNames":["Avandia"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"},{"label":"4","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being carried out to see if dapagliflozin in addition to glimepiride (sulphonylurea) is effective and safe in treating patients with type 2 diabetes when compared to glimepiride alone.","primaryOutcome":{"measure":"Adjusted Mean Change in HbA1c Levels","timeFrame":"Baseline to Week 24","effectByArm":[{"arm":"Dapagliflozin 2.5mg + Glimepiride","deltaMin":-0.58,"sd":null},{"arm":"Dapagliflozin 5mg + Glimepiride","deltaMin":-0.63,"sd":null},{"arm":"Dapagliflozin 10mg + Glimepiride","deltaMin":-0.82,"sd":null},{"arm":"Placebo + Glimepiride","deltaMin":-0.13,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":66,"countries":["Czechia","Hungary","Philippines","Poland","South Korea","Thailand","Ukraine"]},"refs":{"pmids":["33368935","23529567","21672123"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":154},"commonTop":["Hypoglycemia","NASOPHARYNGITIS","HYPERTENSION"]}}